Logo image of PRDS

PARDES BIOSCIENCES INC (PRDS) Stock Fundamental Analysis

USA - NASDAQ:PRDS - US69945Q1058 - Common Stock

2.16 USD
0 (0%)
Last: 8/30/2023, 8:00:01 PM
2.17 USD
+0.01 (+0.46%)
After Hours: 8/30/2023, 8:00:01 PM
Fundamental Rating

3

Overall PRDS gets a fundamental rating of 3 out of 10. We evaluated PRDS against 534 industry peers in the Biotechnology industry. While PRDS has a great health rating, there are worries on its profitability. PRDS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PRDS had negative earnings in the past year.
In the past year PRDS has reported a negative cash flow from operations.
PRDS Yearly Net Income VS EBIT VS OCF VS FCFPRDS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 -20M -40M -60M -80M

1.2 Ratios

The profitability ratios for PRDS are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PRDS Yearly ROA, ROE, ROICPRDS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 0 -100 -200 -300

1.3 Margins

PRDS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRDS Yearly Profit, Operating, Gross MarginsPRDS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022

More info and screens

9

2. Health

2.1 Basic Checks

The number of shares outstanding for PRDS has been reduced compared to 1 year ago.
There is no outstanding debt for PRDS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PRDS Yearly Shares OutstandingPRDS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 20M 40M 60M
PRDS Yearly Total Debt VS Total AssetsPRDS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 39.62 indicates that PRDS is not in any danger for bankruptcy at the moment.
The Altman-Z score of PRDS (39.62) is better than 97.77% of its industry peers.
There is no outstanding debt for PRDS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 39.62
ROIC/WACCN/A
WACCN/A
PRDS Yearly LT Debt VS Equity VS FCFPRDS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 0 100M 200M

2.3 Liquidity

PRDS has a Current Ratio of 81.72. This indicates that PRDS is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of PRDS (81.72) is better than 99.83% of its industry peers.
PRDS has a Quick Ratio of 81.72. This indicates that PRDS is financially healthy and has no problem in meeting its short term obligations.
PRDS has a Quick ratio of 81.72. This is amongst the best in the industry. PRDS outperforms 99.83% of its industry peers.
Industry RankSector Rank
Current Ratio 81.72
Quick Ratio 81.72
PRDS Yearly Current Assets VS Current LiabilitesPRDS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

PRDS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.75%, which is quite good.
EPS 1Y (TTM)12.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

PRDS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.50% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y27.93%
EPS Next 2Y29.94%
EPS Next 3Y18.5%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PRDS Yearly EPS VS EstimatesPRDS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PRDS. In the last year negative earnings were reported.
Also next year PRDS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRDS Price Earnings VS Forward Price EarningsPRDS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRDS Per share dataPRDS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PRDS's earnings are expected to grow with 18.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.94%
EPS Next 3Y18.5%

More info and screens

0

5. Dividend

5.1 Amount

PRDS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PARDES BIOSCIENCES INC

NASDAQ:PRDS (8/30/2023, 8:00:01 PM)

After market: 2.17 +0.01 (+0.46%)

2.16

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-04 2023-08-04/amc
Earnings (Next)11-06 2023-11-06/amc
Inst Owners6.52%
Inst Owner Change-90.03%
Ins Owners6.54%
Ins Owner Change0%
Market Cap133.95M
Revenue(TTM)N/A
Net Income(TTM)-76137000
Analysts43.33
Price Target1.27 (-41.2%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)40.62%
Min EPS beat(2)27.68%
Max EPS beat(2)53.56%
EPS beat(4)4
Avg EPS beat(4)31.85%
Min EPS beat(4)20.14%
Max EPS beat(4)53.56%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-28.57%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-383.33%
EPS NY rev (1m)0%
EPS NY rev (3m)-26.43%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.86
P/tB 0.86
EV/EBITDA N/A
EPS(TTM)-1.29
EYN/A
EPS(NY)-0.52
Fwd EYN/A
FCF(TTM)-1.27
FCFYN/A
OCF(TTM)-1.27
OCFYN/A
SpS0
BVpS2.51
TBVpS2.51
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 81.72
Quick Ratio 81.72
Altman-Z 39.62
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.5%
EPS Next Y27.93%
EPS Next 2Y29.94%
EPS Next 3Y18.5%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y5.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-94.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-94.96%
OCF growth 3YN/A
OCF growth 5YN/A

PARDES BIOSCIENCES INC / PRDS FAQ

Can you provide the ChartMill fundamental rating for PARDES BIOSCIENCES INC?

ChartMill assigns a fundamental rating of 3 / 10 to PRDS.


Can you provide the valuation status for PARDES BIOSCIENCES INC?

ChartMill assigns a valuation rating of 0 / 10 to PARDES BIOSCIENCES INC (PRDS). This can be considered as Overvalued.


How profitable is PARDES BIOSCIENCES INC (PRDS) stock?

PARDES BIOSCIENCES INC (PRDS) has a profitability rating of 0 / 10.


What is the financial health of PARDES BIOSCIENCES INC (PRDS) stock?

The financial health rating of PARDES BIOSCIENCES INC (PRDS) is 9 / 10.